Celsion Corp., of Lawrenceville, N.J., disclosed updated results from its retrospective analysis of the company's 701-patient Heat study of Thermodox, heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA) in primary liver cancer.